Modra, taking a leaf out of the Paxlovid playbook, validates oral delivery of chemotherapy in the clinicnews2022-02-22T11:21:48+00:00February 22nd, 2022|Fierce Pharma|
Pfizer gets EU approval for long-acting human growth hormone, softening blow of FDA rejectionnews2022-02-22T11:17:04+00:00February 22nd, 2022|Fierce Pharma|
PolyActiva’s glaucoma implant cuts pressure in clinical test, opening the door to further developmentnews2022-02-22T11:09:12+00:00February 22nd, 2022|Fierce Pharma|
Oncologists on board for Novartis’ prostate cancer radiotherapy, but logistics could hit uptake: surveynews2022-02-21T16:05:46+00:00February 21st, 2022|Fierce Pharma|
Bristol Myers Squibb, GRYT Health double down on diversity in cancernews2022-02-18T16:36:39+00:00February 18th, 2022|Fierce Pharma|
Sandoz launches generic Revlimid in 19 countries in Europe, opening a flood of competition for BMS’ megablockbusternews2022-02-18T16:17:47+00:00February 18th, 2022|Fierce Pharma|
Roche settles lawsuit claiming AstraZeneca’s Ultomiris infringes delivery patentnews2022-02-18T14:51:01+00:00February 18th, 2022|Fierce Pharma|
Sanofi, Regeneron ditch Dupixent trial vs. Novartis and Roche’s Xolair for hives conditionnews2022-02-18T14:50:48+00:00February 18th, 2022|Fierce Pharma|
Sanofi, Regeneron ditch Dupixent trial in patients who failed Novartis and Roche’s Xolair for hives conditionnews2022-02-18T14:50:48+00:00February 18th, 2022|Fierce Pharma|
Recipharm, working on Moderna’s COVID vaccine, boosts biologics presence with Arranta Bio, Vibalogics buyoutsnews2022-02-18T14:47:00+00:00February 18th, 2022|Fierce Pharma|
